Abstract
AbstractDownregulation of HLA class I (HLA-I) impairs immune recognition and surveillance in prostate cancer and may underlie the ineffectiveness of checkpoint blockade. However, the molecular mechanisms regulating HLA-I loss in prostate cancer have not been fully explored. Here, we conducted a comprehensive analysis of HLA-I genomic, epigenomic and gene expression alterations in primary and metastatic human prostate cancer. Loss of HLA-I gene expression was associated with repressive chromatin states including DNA methylation, histone H3 tri-methylation at lysine 27, and reduced chromatin accessibility. Pharmacological DNA methyltransferase (DNMT) and histone deacetylase (HDAC) inhibition decreased DNA methylation and increased H3 lysine 27 acetylation and resulted in re-expression of HLA-I on the surface of tumor cells. Re-expression of HLA-I on LNCaP cells by DNMT and HDAC inhibition increased activation of co-cultured prostate specific membrane antigen (PSMA)27-38-specific CD8+ T-cells. HLA-I expression is epigenetically regulated by functionally reversible DNA methylation and chromatin modifications in human prostate cancer. Methylated HLA-I was detected in HLA-Ilow circulating tumor cells (CTCs), which may serve as a minimally invasive biomarker for identifying patients who would benefit from epigenetic targeted therapies.
Funder
Office of the Assistant Secretary of Defense for Health Affairs through the Prostate Cancer Research Program
National Cancer Institute of the National Institutes of Health
Office of the Assistant Secretary of Defense for Health Affairs through the Prostate Cancer Research Program National Cancer Institute of the National Institutes of Health
Publisher
Springer Science and Business Media LLC
Subject
General Agricultural and Biological Sciences,General Biochemistry, Genetics and Molecular Biology,Medicine (miscellaneous)
Reference60 articles.
1. Kelly, S. P., Anderson, W. F., Rosenberg, P. S. & Cook, M. B. Past, current, and future incidence rates and burden of metastatic prostate cancer in the United States. Eur. Urol. Focus 4, 121–127 (2018).
2. Howlader, N. et al. (eds). SEER Cancer Statistics Review, 1975–2018 (National Cancer Institute, Bethesda, MD, 2021). https://seer.cancer.gov/csr/1975_2018/.
3. Boettcher, A. N. et al. Past, current, and future of immunotherapies for prostate cancer. Front Oncol. 9, 884 (2019).
4. Schweizer, M. T. & Drake, C. G. Immunotherapy for prostate cancer: recent developments and future challenges. Cancer Metastasis Rev. 33, 641–655 (2014).
5. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献